Details of the Drug
General Information of Drug (ID: DMFHDWG)
| Drug Name |
5,7-dichloro-1H-indole-2,3-dione
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
5,7-Dichloroisatin; 6374-92-1; 5,7-Dichloroindoline-2,3-dione; 5,7-Dichloro-1H-indole-2,3-dione; 1H-Indole-2,3-dione, 5,7-dichloro-; NSC26045; 5,7-dichloro-2,3-dihydro-1H-indole-2,3-dione; MLS002639083; AYGGQJHJRFZDFH-UHFFFAOYSA-N; 5,7-dichloro-1H-benzo[d]azolidine-2,3-dione; 5,7-dichlor-1h-indol-2,3-dion; EINECS 228-928-3; Indole-2,3-dione, 5,7-dichloro-; Isatin,7-dichloro-; PubChem22561; AC1Q3MQY; Isatin, 5,7-dichloro-; ACMC-1B7TC; NCIMech_000038; Isatin-based compound, 53; Cambridge id 5228213; AC1Q3I9X; CBDivE_012174
|
||||||||||||||||||
| Indication |
|
||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 216.02 | |||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 2 | ||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 0 | ||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||
| Drug-Molecule Activity Atlas (DMA)NEW | Click to Jump to the Detailed DMA Information of This Drug | ||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||
|
||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||


